Przemysław Nowakowski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Przemysław Nowakowski has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Wojciech Uchto
Academy of Silesia, Katowice, Poland
5 shared publications- Eugeniusz Hrycek
American Heart of Poland, Topolowa 16, 32-500 Chrzanów, Poland
4 shared publications - Aleksander Zurakowski
American Heart of Poland, Topolowa 16, 32-500 Chrzanów, Poland
3 shared publications - Krzysztof Milewski
American Heart of Poland, ul. Armii Krajowej 101, 43-316 Bielsko-Biała, Poland
3 shared publications - Piotr Buszman
Department of Cardiology, Faculty of Medical Sciences, Andrzej Frycz Modrzewski Krakow University, 30-705 Krakow, Poland
3 shared publications - Andrew Holden
Department of Interventional Radiology, Auckland Hospital, Auckland, New Zealand
2 shared publications
Latest Publications
- Open Access
- 15 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (24) , 8858
Should the Approach to Pre-Procedural Cardiological Diagnostics in Patients with Peripheral Artery Disease Be Reconsidered? The Prevalence of Coronary Artery Disease in Asymptomatic Patients
Background/Objectives: Patients with peripheral arterial disease (PAD) or carotid stenosis (CS) who do not exhibit symptoms suggesting the coexistence of CAD are often not evaluated for CAD. The aim of this study was to assess the prevalence of asymptomatic CAD identified by coronary angiography in patients with PAD or CS, undergoing peripheral arteriography, and without prior diagnosis of CAD. Methods: A total of 350 PAD patients undergoing peripheral angiography, without a history or symptoms of CAD were prospectively enrolled in this study. These patients underwent simultaneous coronary angiography during scheduled peripheral arteriography. The severity of CAD was assessed using the Jeopardy Score Scale (JSC) and by evaluating the number of major coronary vessels involved. Results: Significant coronary artery stenosis was detected in 52.86%, with 50.00% in the PAD group and 51.43% in the CS group. One-, two-, and three-vessel disease was present in 29.14%, 14.28%, and 10.01% of the study population, respectively. The JSC median for the entire cohort was 2 (0–4) and 4 (2–8) when CAD was diagnosed. The combination of CS and PAD was associated with the highest risk for CAD (73%), with a median JSC of 2 (0–8). Conclusions: The risk of co-occurrence of CAD in patients with PAD, regardless of the presence of CAD symptoms, is high, exceeding 50%. Consequently, (in accordance with the guidelines for the management of chronic coronary syndromes), in all patients with PAD, regardless of CAD symptoms, advanced cardiological diagnostics, including coronary CT angiography or functional imaging, should be considered.
- 15 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (24) , 8858
Open AccessShould the Approach to Pre-Procedural Cardiological Diagnostics in Patients with Peripheral Artery Disease Be Reconsidered? The Prevalence of Coronary Artery Disease in Asymptomatic Patients
Background/Objectives: Patients with peripheral arterial disease (PAD) or carotid stenosis (CS) who do not exhibit symptoms suggesting the coexistence of CAD are often not evaluated for CAD. The aim of this study was to assess the prevalence of asymptomatic CAD identified by coronary angiography in patients with PAD or CS, undergoing peripheral arteriography, and without prior diagnosis of CAD. Methods: A total of 350 PAD patients undergoing peripheral angiography, without a history or symptoms of CAD were prospectively enrolled in this study. These patients underwent simultaneous coronary angiography during scheduled peripheral arteriography. The severity of CAD was assessed using the Jeopardy Score Scale (JSC) and by evaluating the number of major coronary vessels involved. Results: Significant coronary artery stenosis was detected in 52.86%, with 50.00% in the PAD group and 51.43% in the CS group. One-, two-, and three-vessel disease was present in 29.14%, 14.28%, and 10.01% of the study population, respectively. The JSC median for the entire cohort was 2 (0–4) and 4 (2–8) when CAD was diagnosed. The combination of CS and PAD was associated with the highest risk for CAD (73%), with a median JSC of 2 (0–8). Conclusions: The risk of co-occurrence of CAD in patients with PAD, regardless of the presence of CAD symptoms, is high, exceeding 50%. Consequently, (in accordance with the guidelines for the management of chronic coronary syndromes), in all patients with PAD, regardless of CAD symptoms, advanced cardiological diagnostics, including coronary CT angiography or functional imaging, should be considered.
- Open Access
- 18 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (8) , 2814
Long-Term Performance and Safety of the Self-Expandable Carotid Stent MER: 5-Year Outcomes from the OCEANUS Study, with Subgroup Analysis Based on Predilatation Before Carotid Artery Stenting
Background: Carotid artery stenting (CAS) with neuroprotection is a widely used treatment for carotid artery stenosis. This study aimed to evaluate the long-term outcomes of CAS using the MER stent (Balton, Poland) and various neuroprotection devices, with subgroup analysis based on predilatation. Methods: A prospective analysis was conducted on patients treated with CAS at four high-volume centers in Poland between October 2016 and May 2017. Patients were stratified into two groups based on whether predilatation was performed. Procedural and clinical outcomes, including major adverse events (MAEs) defined as all-cause death, stroke, and myocardial infarction (MI), were evaluated at 30 days and 5 years post-procedure. Kaplan–Meier analysis and Cox regression models were used to assess event-free survival and predictors of MAEs. Results: The study population consisted of 100 patients (males: 61%) with a mean age of 68 years. Dyslipidemia (84.4% vs. 60.0%, p = 0.007) and smoking (67.3% vs. 44.4%, p = 0.022) differed significantly between the predilatation and non-predilatation groups. The procedural success rate (p = 0.03). Conclusions: CAS with the MER stent demonstrated high procedural success and favorable long-term outcomes. Predilatation did not impact outcomes. Neuroprotection was effective in all cases, with no device-related complications reported.
- 18 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (8) , 2814
Open AccessLong-Term Performance and Safety of the Self-Expandable Carotid Stent MER: 5-Year Outcomes from the OCEANUS Study, with Subgroup Analysis Based on Predilatation Before Carotid Artery Stenting
Background: Carotid artery stenting (CAS) with neuroprotection is a widely used treatment for carotid artery stenosis. This study aimed to evaluate the long-term outcomes of CAS using the MER stent (Balton, Poland) and various neuroprotection devices, with subgroup analysis based on predilatation. Methods: A prospective analysis was conducted on patients treated with CAS at four high-volume centers in Poland between October 2016 and May 2017. Patients were stratified into two groups based on whether predilatation was performed. Procedural and clinical outcomes, including major adverse events (MAEs) defined as all-cause death, stroke, and myocardial infarction (MI), were evaluated at 30 days and 5 years post-procedure. Kaplan–Meier analysis and Cox regression models were used to assess event-free survival and predictors of MAEs. Results: The study population consisted of 100 patients (males: 61%) with a mean age of 68 years. Dyslipidemia (84.4% vs. 60.0%, p = 0.007) and smoking (67.3% vs. 44.4%, p = 0.022) differed significantly between the predilatation and non-predilatation groups. The procedural success rate (p = 0.03). Conclusions: CAS with the MER stent demonstrated high procedural success and favorable long-term outcomes. Predilatation did not impact outcomes. Neuroprotection was effective in all cases, with no device-related complications reported.
- Open Access
- 1 January 2025
- Published by Termedia Sp. z.o.o. in Advances in Interventional Cardiology
- Vol. 21 (3) , 409-415
Safety and effectiveness of iliac artery stenosis treatment using percutaneous radial or brachial access: 30-day and 12-month outcomes from the IRBIS registry
Introduction: Radial or brachial access for endovascular treatment of peripheral arterial disease may reduce access site complications and avoid the need for post-procedure immobilization. Aim: This study evaluated in-hospital, 30-day, and 12-month outcomes for iliac artery lesion treatment...
- 1 January 2025
- Published by Termedia Sp. z.o.o. in Advances in Interventional Cardiology
- Vol. 21 (3) , 409-415
Open AccessSafety and effectiveness of iliac artery stenosis treatment using percutaneous radial or brachial access: 30-day and 12-month outcomes from the IRBIS registry
Introduction: Radial or brachial access for endovascular treatment of peripheral arterial disease may reduce access site complications and avoid the need for post-procedure immobilization. Aim: This study evaluated in-hospital, 30-day, and 12-month outcomes for iliac artery lesion treatment...
- Open Access
The Influence of SARS-CoV-2 Vaccination on the Mortality and Outcomes of Patients with Both Myocardial Infarction and COVID-19
Background: This multi-site retrospective analysis with a control group was devised to evaluate the impact of prophylactic SARS-CoV-2 vaccination the on outcomes of myocardial infarction (MI) patients with confirmed COVID-19. Methods: An overall of 129 subjects who had been diagnosed with COVID-19 and MI were included in the analysis and were divided into the study group (44 vaccinated patients) and the control group (85 non-vaccinated comparable patients). The primary outcome measure was defined as the time until in-hospital death, while the secondary outcome measure was defined as the time until death outside the hospital setting. Results: According to in-hospital mortality analysis, 1 (2.27%) subject died in the study group, whereas a total of 19 (22.4%) subjects died among the controls (OR = 0.08; CI: 0.001–0.553; p = 0.023). The impact of vaccination on the in-hospital outcomes of patients treated for COVID-19 and MI was further confirmed using Cox regression analysis (HR: 0.1 CI: 0.01–0.77; p = 0.026). The observed difference was the absence of respiratory failure requiring mechanical ventilation in the study group, whereas it was observed in 14 (16.47%) patients in the control group. During out-of-hospital observation, there were no observed differences in mortality (OR: 1.56; 95% CI: 0.21–11.52; p = 0.66). Conclusions: The complete prophylactic SARS-CoV-2 vaccination course demonstrates a protective role in patients undergoing treatment for MI with confirmed COVID-19 during in-hospital observation.
Open AccessThe Influence of SARS-CoV-2 Vaccination on the Mortality and Outcomes of Patients with Both Myocardial Infarction and COVID-19
Background: This multi-site retrospective analysis with a control group was devised to evaluate the impact of prophylactic SARS-CoV-2 vaccination the on outcomes of myocardial infarction (MI) patients with confirmed COVID-19. Methods: An overall of 129 subjects who had been diagnosed with COVID-19 and MI were included in the analysis and were divided into the study group (44 vaccinated patients) and the control group (85 non-vaccinated comparable patients). The primary outcome measure was defined as the time until in-hospital death, while the secondary outcome measure was defined as the time until death outside the hospital setting. Results: According to in-hospital mortality analysis, 1 (2.27%) subject died in the study group, whereas a total of 19 (22.4%) subjects died among the controls (OR = 0.08; CI: 0.001–0.553; p = 0.023). The impact of vaccination on the in-hospital outcomes of patients treated for COVID-19 and MI was further confirmed using Cox regression analysis (HR: 0.1 CI: 0.01–0.77; p = 0.026). The observed difference was the absence of respiratory failure requiring mechanical ventilation in the study group, whereas it was observed in 14 (16.47%) patients in the control group. During out-of-hospital observation, there were no observed differences in mortality (OR: 1.56; 95% CI: 0.21–11.52; p = 0.66). Conclusions: The complete prophylactic SARS-CoV-2 vaccination course demonstrates a protective role in patients undergoing treatment for MI with confirmed COVID-19 during in-hospital observation.
- Open Access
- 1 January 2024
- Published by Open Access Text Pvt, Ltd. in Journal of Radiology Case Reports
- Vol. 18 (9) , 57-62
Angioplasty of the Middle Cerebral Artery as a Treatment of Ischemic Stroke Developed in the Course of a Routine Diagnostic Angiography – A Case Report
Neurological events are one of possible complications which may occur in the course of invasive diagnostic and therapeutic procedures within aortic arch and coronary territory. The current case describes a patient in whom symptoms of massive stroke occurred immediately after routine coronary and peripheral angiography, treated by MCA angioplasty.
- 1 January 2024
- Published by Open Access Text Pvt, Ltd. in Journal of Radiology Case Reports
- Vol. 18 (9) , 57-62
Open AccessAngioplasty of the Middle Cerebral Artery as a Treatment of Ischemic Stroke Developed in the Course of a Routine Diagnostic Angiography – A Case Report
Neurological events are one of possible complications which may occur in the course of invasive diagnostic and therapeutic procedures within aortic arch and coronary territory. The current case describes a patient in whom symptoms of massive stroke occurred immediately after routine coronary and peripheral angiography, treated by MCA angioplasty.
- Open Access
- 11 September 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (18) , 5899
The Influence of SARS-CoV-2 Infection on Acute Myocardial Infarction Outcomes
Background: This multicenter retrospective study with a control group was designed to assess the influence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on the outcomes of patients with myocardial infarction (MI). Methods: A total of 129 patients with COVID-19 who were treated for MI were included in this study. The control group comprised 129 comparable patients without SARS-CoV-2 infection. The in-hospital, out-of-hospital, and overall mortality were analyzed. Results: A total of thirty-one (24%) patients died in the study group, and two (1.6%) patients died in the control group (OR = 20.09; CI: 4.69–85.97; p < 0.001). Similar results were observed in all analyzed patient subgroups. Multivariable Cox regression analysis confirmed the significant influence of SARS-CoV-2 infection on in-hospital outcomes (HR: 8.48459; CI: 1.982–36.320; p = 0.004). Subanalysis of the groups with COVID-19 plus ST-elevation MI (STEMI) or non-ST-elevation MI (NSTEMI) revealed comparable mortality rates: 14 (21.12%) patients in the NSTEMI group and 17 (26.98%) patients in the STEMI subgroup died (OR: 1.3; CI: 0.56–3.37; p = 0.45). During out-of-hospital observation, no differences in mortality were observed (OR: 0.77; CI: 0.11–4.07; p = 0.73). Conclusions: SARS-CoV-2 infection affects the in-hospital outcomes of patients with both MI and COVID-19, regardless of MI type (STEMI vs. NSTEMI).
- 11 September 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (18) , 5899
Open AccessThe Influence of SARS-CoV-2 Infection on Acute Myocardial Infarction Outcomes
Background: This multicenter retrospective study with a control group was designed to assess the influence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on the outcomes of patients with myocardial infarction (MI). Methods: A total of 129 patients with COVID-19 who were treated for MI were included in this study. The control group comprised 129 comparable patients without SARS-CoV-2 infection. The in-hospital, out-of-hospital, and overall mortality were analyzed. Results: A total of thirty-one (24%) patients died in the study group, and two (1.6%) patients died in the control group (OR = 20.09; CI: 4.69–85.97; p < 0.001). Similar results were observed in all analyzed patient subgroups. Multivariable Cox regression analysis confirmed the significant influence of SARS-CoV-2 infection on in-hospital outcomes (HR: 8.48459; CI: 1.982–36.320; p = 0.004). Subanalysis of the groups with COVID-19 plus ST-elevation MI (STEMI) or non-ST-elevation MI (NSTEMI) revealed comparable mortality rates: 14 (21.12%) patients in the NSTEMI group and 17 (26.98%) patients in the STEMI subgroup died (OR: 1.3; CI: 0.56–3.37; p = 0.45). During out-of-hospital observation, no differences in mortality were observed (OR: 0.77; CI: 0.11–4.07; p = 0.73). Conclusions: SARS-CoV-2 infection affects the in-hospital outcomes of patients with both MI and COVID-19, regardless of MI type (STEMI vs. NSTEMI).
- Open Access
- 1 January 2023
- Published by Termedia Sp. z.o.o. in Advances in Interventional Cardiology
- Vol. 19 (1) , 67-69
Endovascular treatment of infrarenal aortic aneurysm using the ANKURA stent graft – one-center case series
- 1 January 2023
- Published by Termedia Sp. z.o.o. in Advances in Interventional Cardiology
- Vol. 19 (1) , 67-69
Open AccessEndovascular treatment of infrarenal aortic aneurysm using the ANKURA stent graft – one-center case series
- 20 November 2021
- Published by SAGE Publications in Journal of Endovascular Therapy
- Vol. 29 (4) , 586-593
Prospective Study of Serration Angioplasty in the Infrapopliteal Arteries Using the Serranator Device: PRELUDE BTK Study
Purpose: The purpose was to evaluate the safety and efficacy of the Serranator percutaneous transluminal angioplasty serration balloon catheter in patients with infrapopliteal peripheral artery disease. Materials and Methods: A prospective, multicenter, single-arm feasibility study in 46 patients with claudication or chronic limb-threatening ischemia, Rutherford Clinical Category (RCC) 3 to 5, that required treatment of the infrapopliteal arteries above the tibiotalar joint. The primary efficacy outcome was device success—successful insertion, balloon inflation and deflation, and removal of the device(s) with a final diameter stenosis of <50%. The primary safety endpoint was a composite of major adverse limb events (MALE) and perioperative death (POD) through 30 day postprocedure. Other outcomes were change in RCC and ankle-brachial index, wound healing, and clinically-driven target lesion revascularization (CD-TLR). A subset of 9 patients were further evaluated by optical coherence tomography (OCT) or intravascular ultrasound (IVUS) for the presence of serrations in treated lesions. Patient follow-up occurred at 30 days and 6 months. Results: Forty-six patients received treatment with the Serranator device and 55 lesions were treated. Fifty-three lesions were deemed analyzable by the core lab with data and reported hereafter. Device success was 91.7% and freedom from MALE + POD through 30 days was 95.7%. Pretreatment stenosis of 82% was reduced to 21.8% and only 1 lesion (1.9%) required a bailout stent for a grade D dissection. The average maximum balloon inflation pressure was 6 atmospheres. Serrations were present in all treated lesions (n=10) in 9 patients imaged with OCT/IVUS as reviewed by the core laboratory. The RCC score improved by 1 or more level in 70% of patients at 6 months with 42% having a score of 0. The 6 month freedom from CD-TLR was 97.7%. Conclusion: Serranator treatment of infrapopliteal lesions showed excellent lumen gain with minimal evidence of arterial injury and low 6 month CD-TLR. Imaging by IVUS and OCT showed serrations without significant dissection, supporting the device’s proposed mechanism of action.
- 20 November 2021
- Published by SAGE Publications in Journal of Endovascular Therapy
- Vol. 29 (4) , 586-593
Prospective Study of Serration Angioplasty in the Infrapopliteal Arteries Using the Serranator Device: PRELUDE BTK Study
Purpose: The purpose was to evaluate the safety and efficacy of the Serranator percutaneous transluminal angioplasty serration balloon catheter in patients with infrapopliteal peripheral artery disease. Materials and Methods: A prospective, multicenter, single-arm feasibility study in 46 patients with claudication or chronic limb-threatening ischemia, Rutherford Clinical Category (RCC) 3 to 5, that required treatment of the infrapopliteal arteries above the tibiotalar joint. The primary efficacy outcome was device success—successful insertion, balloon inflation and deflation, and removal of the device(s) with a final diameter stenosis of <50%. The primary safety endpoint was a composite of major adverse limb events (MALE) and perioperative death (POD) through 30 day postprocedure. Other outcomes were change in RCC and ankle-brachial index, wound healing, and clinically-driven target lesion revascularization (CD-TLR). A subset of 9 patients were further evaluated by optical coherence tomography (OCT) or intravascular ultrasound (IVUS) for the presence of serrations in treated lesions. Patient follow-up occurred at 30 days and 6 months. Results: Forty-six patients received treatment with the Serranator device and 55 lesions were treated. Fifty-three lesions were deemed analyzable by the core lab with data and reported hereafter. Device success was 91.7% and freedom from MALE + POD through 30 days was 95.7%. Pretreatment stenosis of 82% was reduced to 21.8% and only 1 lesion (1.9%) required a bailout stent for a grade D dissection. The average maximum balloon inflation pressure was 6 atmospheres. Serrations were present in all treated lesions (n=10) in 9 patients imaged with OCT/IVUS as reviewed by the core laboratory. The RCC score improved by 1 or more level in 70% of patients at 6 months with 42% having a score of 0. The 6 month freedom from CD-TLR was 97.7%. Conclusion: Serranator treatment of infrapopliteal lesions showed excellent lumen gain with minimal evidence of arterial injury and low 6 month CD-TLR. Imaging by IVUS and OCT showed serrations without significant dissection, supporting the device’s proposed mechanism of action.
- 9 March 2021
- Published by SAGE Publications in Vascular Medicine
- Vol. 26 (4) , 401-408
Microcrystalline paclitaxel-coated balloon for revascularization of femoropopliteal artery disease: Three-year outcomes of the randomized BIOPAC trial
The aim of the BIOPAC trial was to determine long-term safety and efficacy of a novel microcrystalline paclitaxel-coated balloon (mcPCB) with a biocompatible polymer as an excipient in the treatment of occlusive femoropopliteal lesions. In this first-in-human prospective controlled randomized trial, 66 patients with femoropopliteal, symptomatic (Rutherford stages 2B to 5) occlusive arterial disease were randomized to either mcPCB (study group) or POBA (plain old balloon angioplasty) (control group) on a 1:1 basis. Late lumen loss (LLL) at 6 months was the primary endpoint of the study and serious adverse events (SAE: death, amputation, repeated revascularization) were considered a composite secondary endpoint. Routine angiography was scheduled for all study subjects at 6-month follow-up; outpatient appointments were scheduled at 12 and 36 months after intervention. At 6 months, the LLL was 63% lower in the mcPCB group compared to the POBA group (0.52 ± 1.2 vs 1.39 ± 1.1 mm; psup < 0.01). Binary restenosis occurred in 23% vs 52% of patients ( p = 0.02). At 3 years, the prevalence of SAE was significantly lower in the mcPCB group (33.3 vs 63.3%; p = 0.02), which mainly resulted from a twofold reduction in target vessel revascularization rate (28.6 vs 59.3%; p = 0.02). The difference in mortality was nonsignificant (7.4 vs 14.3%; p = 0.42). Patients with mcPCB were less symptomatic and less likely to adhere to secondary prevention measures. In this pivotal trial, a novel mcPCB proved superior to POBA concerning LLL at 6-month follow-up, and SAE at 12 months. This result was sustained up to 3 years. There was no difference between groups regarding mortality. ClinicalTrials.gov Identifier: NCT02145065
- 9 March 2021
- Published by SAGE Publications in Vascular Medicine
- Vol. 26 (4) , 401-408
Microcrystalline paclitaxel-coated balloon for revascularization of femoropopliteal artery disease: Three-year outcomes of the randomized BIOPAC trial
The aim of the BIOPAC trial was to determine long-term safety and efficacy of a novel microcrystalline paclitaxel-coated balloon (mcPCB) with a biocompatible polymer as an excipient in the treatment of occlusive femoropopliteal lesions. In this first-in-human prospective controlled randomized trial, 66 patients with femoropopliteal, symptomatic (Rutherford stages 2B to 5) occlusive arterial disease were randomized to either mcPCB (study group) or POBA (plain old balloon angioplasty) (control group) on a 1:1 basis. Late lumen loss (LLL) at 6 months was the primary endpoint of the study and serious adverse events (SAE: death, amputation, repeated revascularization) were considered a composite secondary endpoint. Routine angiography was scheduled for all study subjects at 6-month follow-up; outpatient appointments were scheduled at 12 and 36 months after intervention. At 6 months, the LLL was 63% lower in the mcPCB group compared to the POBA group (0.52 ± 1.2 vs 1.39 ± 1.1 mm; psup < 0.01). Binary restenosis occurred in 23% vs 52% of patients ( p = 0.02). At 3 years, the prevalence of SAE was significantly lower in the mcPCB group (33.3 vs 63.3%; p = 0.02), which mainly resulted from a twofold reduction in target vessel revascularization rate (28.6 vs 59.3%; p = 0.02). The difference in mortality was nonsignificant (7.4 vs 14.3%; p = 0.42). Patients with mcPCB were less symptomatic and less likely to adhere to secondary prevention measures. In this pivotal trial, a novel mcPCB proved superior to POBA concerning LLL at 6-month follow-up, and SAE at 12 months. This result was sustained up to 3 years. There was no difference between groups regarding mortality. ClinicalTrials.gov Identifier: NCT02145065
- 1 January 2021
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 61 (1) , 167-168
OCEANUS (PrOspective multiCentEr Study of cArotid Artery steNting Using mer Stent) Study: 30 Day and Two Year Results
- 1 January 2021
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 61 (1) , 167-168
OCEANUS (PrOspective multiCentEr Study of cArotid Artery steNting Using mer Stent) Study: 30 Day and Two Year Results